研究について【2019年】

英文原著論文　Original papers

発刊済のものはabstractまたは本文にリンクしてあります。
Published papers are linked to PubMed


Masuda Y, Takeuchi K, Kodama T, Fujisaki T, Imaizumi Y, Otsuka E, Ozaki S, Hasebe S, Yakushijin Y.
Treatment-associated outcomes of patients with primary ocular adnexal MALT lymphoma after accurate diagnosis.
Int J Clin Oncol. 2019 Dec;24(12):1620-1628


Ueno R, Nishimura S, Fujimoto G, Piao Y, Takenaka K.

The clinical and economic burden of cytomegalovirus management post allogeneic hematopoietic stem cell transplantation in Japan – a retrospective database study.

Curr Med Res Opin. 2019 Dec;35(12):2089-2096.



Watanabe S, Kawakami Y, Kimura H, Murakami S, Miyamoto H, Takatori S, Suemori K, Tanaka M, Tanaka A, Tanaka K, Tauchi H, Maki J, Araki H, Yamaguchi T.

Association between daptomycin susceptibility and teicoplanin resistance in Staphylococcus epidermidis.

Sci Rep. 2019 Dec 6;9(1):18533.



Elbadry MI, Mizumaki H, Hosokawa K, Espinoza JL, Nakagawa N, Chonabayashi K, Yoshida Y, Katagiri T, Hosomichi K, Zaimoku Y, Imi T, Nguyen MAT, Fujii Y, Tajima A, Ogawa S, Takenaka K, Akashi K, Nakao S.
Escape hematopoiesis by HLA-B5401-lacking hematopoietic stem progenitor cells in men with acquired aplastic anemia.
Haematologica. 2019 Mar 19. pii: haematol.2018.210856.[Epub ahead of print]



Maruta M, Ochi T, Tanimoto K, Asai H, Saitou T, Fujiwara H, Imamura T, Takenaka K, Yasukawa M.

Direct comparison of target-reactivity and cross-reactivity induced by CAR- and BiTE-redirected T cells for the development of antibody-based T-cell therapy.

Sci Rep. 2019 Sep 16;9(1):13293.



Murata M, Takenaka K, Uchida N, Ozawa Y, Ohashi K, Kim SW, Ikegame K, Kanda Y, Kobayashi H, Ishikawa J, Ago H, Hirokawa M, Fukuda T, Atsuta Y, Kondo T.
Comparison of Outcomes of Allogeneic Transplantation for Primary Myelofibrosis among Hematopoietic Stem Cell Source Groups.
Biol Blood Marrow Transplant. 2019 Mar 1. pii: S1083-8791(19)30144-2.[Epub ahead of print]


Minami M, Matsushima T, Mori Y, Ishihara D, Jinnnouchi F, Takenaka K, Henzan T, Yoshimoto G, Numata A, Kato K, Maeda T, Miyamoto T, Akashi K.
Successful rescue transplantation with desensitization procedure after primary graft failure due to donor-specific antibody.
Bone Marrow Transplant. 2019 Feb 25.[Epub ahead of print]



Komatsu K, Kinai E, Sakamoto M, Taniguchi T, Nakao A, Sakata T, Iizuka A, Koyama T, Ogata T, Inui A, Oka S; HIV-Associated Neurocognitive Disorders in Japanese (J-HAND) Study Group (The J-HAND Study Group).
Various associations of aging and long-term HIV infection with different neurocognitive functions: detailed analysis of a Japanese nationwide multicenter study.
J Neurovirol. 2019 Apr;25(2):208-220.



Yamada T, Nabe S, Toriyama K, Suzuki J, Inoue K, Imai Y, Shiraishi A, Takenaka K, Yasukawa M, Yamashita M.
Histone H3K27 Demethylase Negatively Controls the Memory Formation of Antigen-Stimulated CD8+ T Cells.
J Immunol. 2019 Feb 15;202(4):1088-1098.



Okada M, Suemori K, Takagi D, Teraoka M, Yamada H, Ishizaki J, Matsumoto T, Hasegawa H, Hato N.
The treatment outcomes of rituximab for intractable otitis media with ANCA-associated vasculitis.
Auris Nasus Larynx. 2019 Feb;46(1):38-42.



Nakano M, Kikushige Y, Miyawaki K, Kunisaki Y, Mizuno S, Takenaka K, Tamura S, Okumura Y, Ito M, Ariyama H, Kusaba H, Nakamura M, Maeda T, Baba E, Akashi K.
Dedifferentiation process driven by TGF-beta signaling enhances stem cell properties in human colorectal cancer.
Oncogene. 2019 Feb;38(6):780-793.


Inagaki Y, Maruta M, Nakano Y, Higuchi J.

Preventability of Early Versus Late Hospital Readmissions.

Ann Intern Med. 2019 Feb 5;170(3):217-218.



Ikeda Y, Yamanouchi J, Hato T, Yasukawa M, Takenaka K.
Safe childbirth for a type 1 antithrombin-deficient woman with novel mutation in the SERPINC1 gene undergoing antithrombin concentrate therapy.
Blood Coagul Fibrinolysis. 2019 Jan;30(1):47-51.



Mori Y, Yoshimoto G, Yuda JI, Hayashi M, Odawara J, Kuriyama T, Sugio T, Miyawaki K, Kamezaki K, Kato K, Takenaka K, Iwasaki H, Maeda T, Miyamoto T, Akashi K.
Previous exposure to bortezomib is linked to a lower risk of engraftment syndrome after autologous hematopoietic stem cell transplantation.
Leuk Lymphoma. 2019 Jan;60(1):271-273.